# Risk: __Lack of access to pharmaceutical interventions__ (PBN__Risk_1158)

## Property: has_RiskISO_Impact

* [Biodiversity and ecosystem services](../RiskISO/PBN__RiskISO_Purpose_4)

## Property: has_RiskTechnology

* [nan](../Technology/PBN__Technology_22)

## Property: has_RiskSubject

* [developing countries](../Stakeholder/PBN__Stakeholder_223)

## Property: has_RiskType

* [technological](../RiskType/PBN__RiskType_5)

## Property: has_RiskISO_Purpose

* [Attractiveness](../RiskISO/PBN__RiskISO_Impact_9)

## Property: has_RiskOwner

* [governments](../Stakeholder/PBN__Stakeholder_47)
* [international organizations](../Stakeholder/PBN__Stakeholder_242)
* [pharmaceutical companies](../Stakeholder/PBN__Stakeholder_124)

## Property: has_RiskMitigation

* [Focus on non-pharmaceutical interventions, prioritize distribution to countries in need](../RiskMitigation/PBN__RiskMitigation_1610)

## Property: has_RiskName

Higher morbidity and mortality rates in affected populations

## Property: has_RiskDescription

Developing countries may not have timely access to antiviral medicines and vaccines

## Property: has_RiskSource

* [bauerle_e-mental_2020](../Article/PBN__Article_209)

## Property: has_RiskGBN

* [No](../RiskGBN/PBN__RiskGBN_0)

## Property: has_RiskHealth

* [physical](../RiskHealth/PBN__RiskHealth_0)

